Reported 1 day ago
Johnson & Johnson exceeded Wall Street expectations with strong first-quarter earnings, driven by robust cancer drug sales. The company raised its 2025 sales forecast by $700 million, but maintained its profit estimate amid potential tariffs stemming from trade tensions. J&J’s total sales reached $21.89 billion, up 2.4% year-over-year, largely supported by a notable increase in Darzalex sales, while also facing challenges in its medical devices segment.
Source: YAHOO